

Kerry Lynn Reynolds

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6125073/publications.pdf>

Version: 2024-02-01

109
papers

5,479
citations

172386

29
h-index

102432

66
g-index

110
all docs

110
docs citations

110
times ranked

5258
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 246-249.	0.6	2
2	Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. <i>American Journal of Kidney Diseases</i> , 2022, 79, 134-137.	2.1	20
3	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	1.0	213
4	Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 507-514.	0.4	10
5	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	0.8	75
6	Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. <i>JAMA Dermatology</i> , 2022, 158, 189.	2.0	60
7	Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2022, 163, 108-118.	1.3	21
8	Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1147-1149.	0.6	4
9	Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1200-1202.	3.0	9
10	Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapy. <i>British Journal of Dermatology</i> , 2022, 187, 424-426.	1.4	1
11	Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2022, 166, 21-23.	1.3	0
12	Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 871452.	2.2	8
13	Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2896-2908.e4.	0.3	9
14	Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer. <i>JAMA Dermatology</i> , 2022, 158, 933.	2.0	20
15	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
16	Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2507-2507.	0.8	1
17	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. <i>Oncologist</i> , 2021, 26, 49-55.	1.9	18
18	Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis. <i>European Journal of Cancer</i> , 2021, 142, 143-146.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Liver biopsy findings in patients on immune checkpoint inhibitors. <i>Modern Pathology</i> , 2021, 34, 426-437.	2.9	48
20	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
21	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2021, 1, Itab014.	1.2	10
22	Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 187-195.	0.2	17
23	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. , 2021, 9, e001935.		38
24	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
25	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiac Toxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	1.7	80
26	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
27	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1503-1516.	1.2	97
28	Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, e898-e901.	1.9	12
29	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. , 2021, 9, e002292.		25
30	Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2655-2655.	0.8	0
31	Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. <i>JAMA Dermatology</i> , 2021, 157, 577.	2.0	31
32	Impact of systemic corticosteroids for cutaneous immune-related adverse events on survival outcomes in patients with advanced cancer: A retrospective cohort study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14523-e14523.	0.8	0
33	Consensus disease definitions for the spectrum of neurologic immune related adverse events.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2647-2647.	0.8	2
34	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. <i>Oncologist</i> , 2021, 26, e1427-e1433.	1.9	11
35	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. <i>Current Treatment Options in Oncology</i> , 2021, 22, 53.	1.3	2
36	Impact of cancer type on the incidence of cutaneous toxicities after immune checkpoint inhibitor therapy: A population-level analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14553-e14553.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 2654-2654.	0.8	0
38	Relationship between insurance status and diagnosis of cutaneous immune-related adverse events.. Journal of Clinical Oncology, 2021, 39, e18535-e18535.	0.8	0
39	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist, 2021, 26, 685-693.	1.9	3
40	Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. European Radiology, 2021, 31, 8868-8878.	2.3	2
41	Pericardial disease in patients treated with immune checkpoint inhibitors. , 2021, 9, e002771.		33
42	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
43	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Cardiology Reports, 2021, 23, 98.	1.3	34
44	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		20
45	Response to: "Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions". Journal of the American Academy of Dermatology, 2021, 85, e111-e112.	0.6	0
46	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
47	Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 157, 50-58.	1.3	9
48	Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrology Dialysis Transplantation, 2021, 36, 2241-2247.	0.4	33
49	Acute kidney injury in patients treated with immune checkpoint inhibitors. , 2021, 9, e003467.		103
50	Immune checkpoint inhibitors for cancer and venous thromboembolic events. European Journal of Cancer, 2021, 158, 99-110.	1.3	35
51	Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid. European Journal of Cancer, 2021, 159, 34-37.	1.3	5
52	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neuro-Oncology Advances, 2021, 3, v108-v120.	0.4	6
53	Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 994-996.	0.6	16
54	Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist, 2020, 25, 6-14.	1.9	31

#	ARTICLE	IF	CITATIONS
55	Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 743-746.	0.6	9
56	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
57	Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. <i>Circulation</i> , 2020, 142, 2299-2311.	1.6	282
58	Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American Heart Association</i> , 2020, 9, e018306.	1.6	38
59	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020, 25, 997-1000.	1.9	6
60	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.	5.1	74
61	Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. <i>Kidney International Reports</i> , 2020, 5, 1700-1705.	0.4	47
62	Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. , 2020, 8, e001329.		11
63	Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. <i>JAMA Network Open</i> , 2020, 3, e2016144.	2.8	24
64	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
65	Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. <i>Kidney Medicine</i> , 2020, 2, 373-375.	1.0	5
66	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
67	Randomized trial of a hospice video educational tool for patients with advanced cancer and their caregivers. <i>Cancer</i> , 2020, 126, 3569-3578.	2.0	6
68	Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. <i>New England Journal of Medicine</i> , 2020, 382, 1150-1159.	13.9	7
69	Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1475-1477.	0.6	16
70	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. <i>Current Oncology Reports</i> , 2020, 22, 39.	1.8	199
71	Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 2288-2295.	2.0	49
72	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. <i>Annals of Neurology</i> , 2020, 87, 659-669.	2.8	137

#	ARTICLE	IF	CITATIONS
73	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	1.0	212
74	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2838-2848.	3.2	403
75	Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. <i>American Journal of Kidney Diseases</i> , 2020, 76, 63-71.	2.1	74
76	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 467-478.	1.2	179
77	Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 435-446.	3.0	247
78	Diagnostic evaluation of immune checkpoint inhibitor (CPI) colitis: The role of CT scan.. <i>Journal of Clinical Oncology</i> , 2020, 38, 821-821.	0.8	0
79	Atypical Stevens-Johnson syndrome-like reaction in the setting of immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-102.	0.8	0
80	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. <i>Cancer Medicine</i> , 2019, 8, 4986-4999.	1.3	27
81	Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States. <i>JAMA Network Open</i> , 2019, 2, e1911952.	2.8	47
82	Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. <i>Neurology</i> , 2019, 93, e1093-e1103.	1.5	107
83	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
84	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	2.0	51
85	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. <i>Oncologist</i> , 2019, 24, 435-443.	1.9	80
86	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. <i>Oncologist</i> , 2019, 24, 735-742.	1.9	43
87	Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1127-1132.	1.6	56
88	Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>Cancer</i> , 2019, 125, 278-289.	2.0	24
89	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. <i>JAMA Oncology</i> , 2019, 5, 358.	3.4	48
90	Performance status, survival, and end-of-life care in adults with non-small cell lung cancer (NSCLC) treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 49-49.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Factors associated with severity of immune checkpoint inhibitor gastroenterocolitis requiring hospitalization in melanoma patients.. Journal of Clinical Oncology, 2019, 37, 81-81.	0.8	0
92	Flu vaccination rate of patients with severe immune-related adverse events.. Journal of Clinical Oncology, 2019, 37, e18234-e18234.	0.8	1
93	Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting.. Journal of Clinical Oncology, 2019, 37, 6634-6634.	0.8	2
94	Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1755-1764.	1.2	997
95	Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. Blood, 2018, 132, 1037-1037.	0.6	1
96	Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience.. Journal of Clinical Oncology, 2018, 36, 3060-3060.	0.8	4
97	Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2018, 36, 3087-3087.	0.8	2
98	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.. Journal of Clinical Oncology, 2018, 36, 3096-3096.	0.8	4
99	Cost-effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors.. Journal of Clinical Oncology, 2018, 36, 56-56.	0.8	1
100	Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?. Journal of Clinical Oncology, 2018, 36, 127-127.	0.8	10
101	Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis.. Journal of Clinical Oncology, 2018, 36, 829-829.	0.8	0
102	Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers.. Journal of Clinical Oncology, 2018, 36, e16089-e16089.	0.8	0
103	Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, e15134-e15134.	0.8	0
104	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer, 2017, 17, 646.	1.1	24
105	Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. JAMA Oncology, 2016, 2, 1477.	3.4	259
106	Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 586-586.	0.8	0
107	A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. Journal of Clinical Oncology, 2014, 32, 2517-2517.	0.8	10
108	Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 647-647.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer.. Journal of Clinical Oncology, 2013, 31, 147-147.	0.8	1